129 related articles for article (PubMed ID: 10761262)
1. A quality assurance audit: phase III trial of maximal androgen deprivation in prostate cancer (TROG 96.01).
Steigler A; Mameghan H; Lamb D; Joseph D; Matthews J; Franklin I; Turner S; Spry N; Poulsen M; North J; Kovacev O; Denham J
Australas Radiol; 2000 Feb; 44(1):65-71. PubMed ID: 10761262
[TBL] [Abstract][Full Text] [Related]
2. Quality assurance audit in an Australasian phase III trial of accelerated radiotherapy for head and neck cancer (TROG 91.01). Trans-Tasman Radiation Oncology Group.
Hamilton C; Poulsen M; Walker Q; Krawitz H; Hindley A; Spry N; Peters L; Lamb D; Denham J; Steigler A
Australas Radiol; 1999 May; 43(2):227-32. PubMed ID: 10901907
[TBL] [Abstract][Full Text] [Related]
3. Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.
Lamb DS; Denham JW; Mameghan H; Joseph D; Turner S; Matthews J; Franklin I; Atkinson C; North J; Poulsen M; Kovacev O; Robertson R; Francis L; Christie D; Spry NA; Tai KH; Wynne C; Duchesne G
Radiother Oncol; 2003 Sep; 68(3):255-67. PubMed ID: 13129633
[TBL] [Abstract][Full Text] [Related]
4. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.
Pearse M; Fraser-Browne C; Davis ID; Duchesne GM; Fisher R; Frydenberg M; Haworth A; Jose C; Joseph DJ; Lim TS; Matthews J; Millar J; Sidhom M; Spry NA; Tang CI; Turner S; Williams SG; Wiltshire K; Woo HH; Kneebone A
BJU Int; 2014 Mar; 113 Suppl 2():7-12. PubMed ID: 24894850
[TBL] [Abstract][Full Text] [Related]
5. Quality improvements in prostate radiotherapy: outcomes and impact of comprehensive quality assurance during the TROG 03.04 'RADAR' trial.
Kearvell R; Haworth A; Ebert MA; Murray J; Hooton B; Richardson S; Joseph DJ; Lamb D; Spry NA; Duchesne G; Denham JW
J Med Imaging Radiat Oncol; 2013 Apr; 57(2):247-57. PubMed ID: 23551788
[TBL] [Abstract][Full Text] [Related]
6. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results.
Fair WR; Cookson MS; Stroumbakis N; Cohen D; Aprikian AG; Wang Y; Russo P; Soloway SM; Sogani P; Sheinfeld J; Herr H; Dalgabni G; Begg CB; Heston WD; Reuter VE
Urology; 1997 Mar; 49(3A Suppl):46-55. PubMed ID: 9123736
[TBL] [Abstract][Full Text] [Related]
7. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
[TBL] [Abstract][Full Text] [Related]
8. Carcinoma of the prostate: neoadjuvant hormonotherapy followed by radiotherapy.
Scalliet P
Acta Urol Belg; 1996 May; 64(2):63-4. PubMed ID: 8701815
[No Abstract] [Full Text] [Related]
9. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
[TBL] [Abstract][Full Text] [Related]
10. Technical quality assurance during the TROG 03.04 RADAR prostate radiotherapy trial: are the results reflected in observed toxicity rates?
Ebert MA; Bulsara M; Haworth A; Kearvell R; Richardson S; Kennedy A; Spry NA; Bydder SA; Joseph DJ; Denham JW
J Med Imaging Radiat Oncol; 2015 Feb; 59(1):99-108. PubMed ID: 25082363
[TBL] [Abstract][Full Text] [Related]
11. A phase III trial (RTOG 8610) comparing external-beam irradiation plus short-term maximal androgen blockade with radiation therapy alone for locally advanced prostate cancer. The Radiation Therapy Oncology Group.
Eur Urol; 1994; 26 Suppl 1():3. PubMed ID: 7737256
[No Abstract] [Full Text] [Related]
12. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.
Konski A; Watkins-Bruner D; Brereton H; Feigenberg S; Hanks G
Cancer; 2006 Jan; 106(1):51-7. PubMed ID: 16323171
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer.
Bolla M
Eur Urol; 1999; 35 Suppl 1():23-5; discussion 26. PubMed ID: 10081699
[TBL] [Abstract][Full Text] [Related]
14. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
15. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
16. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10.
Shipley WU; Lu JD; Pilepich MV; Heydon K; Roach M; Wolkov HB; Sause WT; Rubin P; Lawton CA; Machtay M
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1302-10. PubMed ID: 12459350
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; King M; Bowe SJ; Stockler MR; Ames A; D'Este C; Frydenberg M; Loblaw A; Malone S; Millar J; Tai KH; Turner S
Lancet Oncol; 2017 Sep; 18(9):1192-1201. PubMed ID: 28760403
[TBL] [Abstract][Full Text] [Related]
18. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.
Pilepich MV; Caplan R; Byhardt RW; Lawton CA; Gallagher MJ; Mesic JB; Hanks GE; Coughlin CT; Porter A; Shipley WU; Grignon D
J Clin Oncol; 1997 Mar; 15(3):1013-21. PubMed ID: 9060541
[TBL] [Abstract][Full Text] [Related]
19. TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol.
Martin J; Keall P; Siva S; Greer P; Christie D; Moore K; Dowling J; Pryor D; Chong P; McLeod N; Raman A; Lynam J; Smart J; Oldmeadow C; Tang CI; Murphy DG; Millar J; Tai KH; Holloway L; Reeves P; Hayden A; Lim T; Holt T; Sidhom M
BMJ Open; 2019 Aug; 9(8):e030731. PubMed ID: 31434782
[TBL] [Abstract][Full Text] [Related]
20. Association between measures of treatment quality and disease progression in prostate cancer radiotherapy: An exploratory analysis from the TROG 03.04 RADAR trial.
Marcello M; Ebert MA; Haworth A; Steigler A; Kennedy A; Bulsara M; Kearvell R; Joseph DJ; Denham JW
J Med Imaging Radiat Oncol; 2018 Apr; 62(2):248-255. PubMed ID: 29222833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
